Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective study of Olaparib in patient with HER2-negative metastatic breast cancer with Germline BRCA mutation or Lesional BRCA mutation

Trial Profile

A Retrospective study of Olaparib in patient with HER2-negative metastatic breast cancer with Germline BRCA mutation or Lesional BRCA mutation

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Olaparib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2018 New trial record
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top